IL96734A - Spray pharmaceuticals containing autoantigens - Google Patents
Spray pharmaceuticals containing autoantigensInfo
- Publication number
- IL96734A IL96734A IL9673490A IL9673490A IL96734A IL 96734 A IL96734 A IL 96734A IL 9673490 A IL9673490 A IL 9673490A IL 9673490 A IL9673490 A IL 9673490A IL 96734 A IL96734 A IL 96734A
- Authority
- IL
- Israel
- Prior art keywords
- mbp
- aerosol
- disease
- autoimmune
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45480689A | 1989-12-20 | 1989-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL96734A0 IL96734A0 (en) | 1991-09-16 |
IL96734A true IL96734A (en) | 1996-11-14 |
Family
ID=23806184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9673490A IL96734A (en) | 1989-12-20 | 1990-12-20 | Spray pharmaceuticals containing autoantigens |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0506785B1 (pt) |
JP (1) | JP2625253B2 (pt) |
KR (1) | KR0185747B1 (pt) |
AT (1) | ATE190496T1 (pt) |
AU (1) | AU642693B2 (pt) |
BR (1) | BR9007950A (pt) |
CA (1) | CA2070281C (pt) |
DE (1) | DE69033487T2 (pt) |
DK (1) | DK0506785T3 (pt) |
ES (1) | ES2144398T3 (pt) |
GR (1) | GR3033634T3 (pt) |
HU (2) | HUT61487A (pt) |
IL (1) | IL96734A (pt) |
WO (1) | WO1991008760A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
JP2607751B2 (ja) * | 1989-07-14 | 1997-05-07 | オートイミューン インク | 自己免疫性ブドウ膜網膜炎の治療予防薬 |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
JP2635444B2 (ja) * | 1990-10-15 | 1997-07-30 | オートイミューン インク | 自己抗体の経口投与による自己免疫性疾患の治療 |
EP0627933B1 (en) * | 1992-02-28 | 2002-11-27 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
JP3845447B2 (ja) * | 1992-09-25 | 2006-11-15 | オートイミューン インク | タイプ▲ii▼コラーゲンによるリウマチ性関節炎治療方法 |
JPH09509135A (ja) * | 1993-06-02 | 1997-09-16 | ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ | 免疫寛容の誘導における利用のためのクリプティックペプチド |
IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
DE69739275D1 (de) * | 1996-01-05 | 2009-04-09 | Autoimmune Inc | Methode zur herstellung von type-ii kollagen |
AUPO269996A0 (en) * | 1996-10-01 | 1996-10-24 | Walter And Eliza Hall Institute Of Medical Research, The | A method of prophylaxis and treatment |
DE69737510T2 (de) | 1996-12-30 | 2007-12-06 | Battelle Memorial Institute, Columbus | Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
SE9902155L (sv) * | 1999-06-09 | 2000-12-10 | Bjoern Rydevik | Serum antibodies |
DE60129552T2 (de) | 2000-05-24 | 2008-04-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | E-selectin zur behandlung oder vorbeugung von schlaganfall |
US7897575B2 (en) | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10230381A1 (de) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
AU2003266081A1 (en) | 2002-09-13 | 2004-04-30 | Universite Laval | Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
WO2007005627A2 (en) | 2005-07-01 | 2007-01-11 | Forsyth Dental Infirmary For Children | Tuberculosis antigen detection assays and vaccines |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2013134577A2 (en) | 2012-03-08 | 2013-09-12 | Detectogen, Inc. | Leishmaniasis antigen detection assays and vaccines |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US379778A (en) * | 1888-03-20 | Machine for mitering printers rules | ||
US65734A (en) * | 1867-06-11 | Joseph fantou | ||
ATE258065T1 (de) * | 1987-06-24 | 2004-02-15 | Brigham & Womens Hospital | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen |
WO1989010409A1 (en) * | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
-
1990
- 1990-12-17 AU AU69791/91A patent/AU642693B2/en not_active Expired
- 1990-12-17 AT AT91901622T patent/ATE190496T1/de not_active IP Right Cessation
- 1990-12-17 DE DE69033487T patent/DE69033487T2/de not_active Expired - Lifetime
- 1990-12-17 HU HU922072A patent/HUT61487A/hu unknown
- 1990-12-17 WO PCT/US1990/007455 patent/WO1991008760A1/en active IP Right Grant
- 1990-12-17 DK DK91901622T patent/DK0506785T3/da active
- 1990-12-17 EP EP91901622A patent/EP0506785B1/en not_active Expired - Lifetime
- 1990-12-17 BR BR909007950A patent/BR9007950A/pt not_active Application Discontinuation
- 1990-12-17 KR KR1019920701486A patent/KR0185747B1/ko not_active IP Right Cessation
- 1990-12-17 JP JP3501992A patent/JP2625253B2/ja not_active Expired - Fee Related
- 1990-12-17 ES ES91901622T patent/ES2144398T3/es not_active Expired - Lifetime
- 1990-12-17 CA CA002070281A patent/CA2070281C/en not_active Expired - Lifetime
- 1990-12-20 IL IL9673490A patent/IL96734A/en not_active IP Right Cessation
-
1995
- 1995-02-15 HU HU95P/P00074P patent/HU210715A9/hu unknown
-
2000
- 2000-06-08 GR GR20000401321T patent/GR3033634T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2625253B2 (ja) | 1997-07-02 |
HU210715A9 (en) | 1995-06-28 |
AU6979191A (en) | 1991-07-18 |
CA2070281A1 (en) | 1991-06-21 |
HU9202072D0 (en) | 1992-09-28 |
KR0185747B1 (ko) | 1999-05-01 |
DE69033487D1 (de) | 2000-04-20 |
EP0506785B1 (en) | 2000-03-15 |
KR920703081A (ko) | 1992-12-17 |
ATE190496T1 (de) | 2000-04-15 |
EP0506785A4 (en) | 1993-09-08 |
AU642693B2 (en) | 1993-10-28 |
BR9007950A (pt) | 1992-10-27 |
DE69033487T2 (de) | 2000-06-29 |
HUT61487A (en) | 1993-01-28 |
IL96734A0 (en) | 1991-09-16 |
DK0506785T3 (da) | 2000-07-24 |
ES2144398T3 (es) | 2000-06-16 |
JPH05504341A (ja) | 1993-07-08 |
EP0506785A1 (en) | 1992-10-07 |
CA2070281C (en) | 2005-08-23 |
GR3033634T3 (en) | 2000-10-31 |
WO1991008760A1 (en) | 1991-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0506785B1 (en) | Improved treatment of autoimmune diseases by aerosol administration of auto antigens | |
US5645820A (en) | Treatment of autoimmune diseases by aerosol administration of autoantigens | |
US5571500A (en) | Treatment of autoimmune diseases through administration by inhalation of autoantigens | |
US5571499A (en) | Treatment of autoimmune diseases by aerosol administration of autoantigens | |
US5641474A (en) | Prevention of autoimmune diseases by aerosol administration of autoantigens | |
AU720695B2 (en) | Bystander suppression of autoimmune diseases | |
EP1033998B1 (en) | Suppressing beta-amyloid-related changes in alzheimer's disease | |
US5783188A (en) | Method of treating rheumatoid arthritis with type collagen peptide fragments containing repeating sequences | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
WO1994007520A9 (en) | Method of treating rheumatoid arthritis with type ii collagen | |
Friedman et al. | Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens | |
WO1994007520A1 (en) | Method of treating rheumatoid arthritis with type ii collagen | |
IL97446A (en) | Medicinal product for the improvement of down-regulation of autoimmune diseases | |
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
KR20000070460A (ko) | 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료 | |
WO1998032451A9 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
JPH09511745A (ja) | 経口寛容および/またはタイプiインターフェロンを用いた自己免疫疾患の治療 | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
CA2410563C (en) | Methods for preventing strokes by inducing tolerance to e-selectin | |
AU2001264813A1 (en) | Methods for preventing strokes by inducing tolerance to E-selectin | |
AU2005235514A1 (en) | Pharmaceutical formulations and methods for preventing or treating damage to brain tissue | |
EP1842551A1 (en) | E-selectin for treating or preventing stroke | |
EP0662838A1 (en) | Method of treating rheumatoid arthritis with type ii collagen | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |